# Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis

> **NCT03540485** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fundación Pública Andaluza para la gestión de la Investigación en Sevilla** · enrollment: 25 (actual)

## Conditions studied

- Sclerosis, Multiple
- Autoimmune Diseases of the Nervous System
- Nervous System Diseases
- Autoimmune Diseases

## Interventions

- **DRUG:** Melatonin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03540485
- **Lead sponsor:** Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-29
- **Primary completion:** 2026-02-18
- **Final completion:** 2026-02-18
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Early termination due to operational feasibility reasons, resulting from a slow recruitment rate and logistical and financial difficulties that prevent reaching the planned sample size within the study schedule.
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03540485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03540485, "Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03540485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*